Block
Jack Dorsey left his post at Twitter for this company, which has huge long-term potential. Block Inc. (NYSE: SQ) creates tools that enable sellers to accept card payments and provides reporting and analytics, as well as next-day settlement.
The company provides the following hardware products:
- Square Register combines its hardware, point-of-sale software and payments technology.
- Square Terminal is a payments device and receipt printer to replace traditional keypad terminals, as it accepts tap, dip and swipe payments.
- Square Stand enables an iPad to be used as a payment terminal or full point-of-sale solution.
- Square Reader for contactless and chip accepts EMV chip cards and NFC payments, enabling acceptance through Apple Pay, Google Pay and other mobile wallets.
- Square Reader for magstripe enables swiped transactions of magnetic-stripe cards by connecting with an iOS or Android smartphone or tablet through the headphone jack or Lightning connector.
The company’s commerce products include Square for Restaurants, Square Appointments, Square for Retail, Square Point of Sale, Square Online, Square Online Checkout, Square Invoices and Square Virtual Terminal, Risk Manager and Order Manager. It offers payment application programming interfaces (APIs) and commerce APIs, as well as Cash App, an ecosystem of financial products and services that enables customers to store, send, receive, spend or invest their money.
Block stock has a 6.0% weighting in the ARK fund. Truist Financial’s $80 target price is less than the $84.93 consensus target, but the shares closed on Friday at $62.86.
Exact Sciences
Anybody who has gone through a colonoscopy can certainly appreciate the products this company makes. Exact Sciences Corp. (NASDAQ: EXAS) provides cancer screening and diagnostic test products globally. Its Cologuard is a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Exact Sciences also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed or recurrent cancer; and COVID-19 testing services.
The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with the MAYO Foundation for Medical Education and Research and with Hologic.
The company has a 5.0% weighting in the ARK fund. Citigroup’s $130 target price tops a consensus target of $100.51. Exact Sciences stock closed at $92.62 on Friday.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
